Furthermore, we propose two potential therapeutic strategies: (1) cholestyramine, an FDA-approved hyperlipidemia medication and (2) HSD3B7 knockdown could serve as viable treatment options for HCC patients with reduced miR-122 in paracancerous tissues. This evidence concerns the gene HSD3B7 and hyperlipidemia.